El Dipòsit Digital ha actualitzat el programari. Contacteu amb dipositdigital@ub.edu per informar de qualsevol incidència.

 

A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis

dc.contributor.authorRapado González, Óscar
dc.contributor.authorMajem, Blanca
dc.contributor.authorÁlvarez Castro, Ana
dc.contributor.authorDíaz Peña, Roberto
dc.contributor.authorAbalo, Alicia
dc.contributor.authorSuárez Cabrera, Leticia
dc.contributor.authorGil Moreno, Antonio
dc.contributor.authorSantamaría, Anna
dc.contributor.authorLópez López, Rafael
dc.contributor.authorMuinelo Romay, Laura
dc.contributor.authorSuarez Cunqueiro, María Mercedes
dc.date.accessioned2020-07-07T15:30:50Z
dc.date.available2020-07-07T15:30:50Z
dc.date.issued2019-12-01
dc.date.updated2020-07-06T08:26:35Z
dc.description.abstractSalivary microRNAs (miRNAs) are of high interest as diagnostic biomarkers for non-oral cancer. However, little is known about their value for colorectal cancer (CRC) detection. Our study aims to characterize salivary miRNAs in order to identify non-invasive markers for CRC diagnosis. The screening of 754 miRNAs was performed in saliva samples from 14 CRC and 10 healthy controls. The differential expressed miRNAs were validated by RT-qPCR in 51 CRC, 19 adenomas and 37 healthy controls. Receiver operating characteristic (ROC) curves and logistic regression models were performed to analyze the clinical value of these miRNAs. Twenty-two salivary miRNAs were significantly deregulated in CRC patients vs. healthy individuals (p < 0.05) in the discovery phase. From those, five upregulated miRNAs (miR-186-5p, miR-29a-3p, miR-29c-3p, miR-766-3p, and miR-491-5p) were confirmed to be significantly higher in the CRC vs. healthy group (p < 0.05). This five-miRNA signature showed diagnostic value (72% sensitivity, 66.67% specificity, AUC = 0.754) to detect CRC, which was even higher in combination with carcinoembryonic antigen (CEA) levels. Overall, after the first global characterization of salivary miRNAs in CRC, a five-miRNA panel was identified as a promising tool to diagnose this malignancy, representing a novel approach to detect cancer-associated epigenetic alterations using a non-invasive strategy.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid31757017
dc.identifier.urihttps://hdl.handle.net/2445/168023
dc.language.isoeng
dc.publisherMdpi
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm8122029
dc.relation.ispartofJournal Of Clinical Medicine, 2019-12-01, Vol. 8, Issue 12
dc.relation.urihttps://doi.org/10.3390/jcm8122029
dc.rightscc by (c) Rapado González, Óscar et al.,2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer colorectal
dc.subject.classificationMarcadors bioquímics
dc.subject.otherColorectal cancer
dc.subject.otherBiochemical markers
dc.titleA Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Rapado-GonzalezO.pdf
Mida:
2.15 MB
Format:
Adobe Portable Document Format